0001225208-24-005706.txt : 20240506 0001225208-24-005706.hdr.sgml : 20240506 20240506191820 ACCESSION NUMBER: 0001225208-24-005706 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240503 FILED AS OF DATE: 20240506 DATE AS OF CHANGE: 20240506 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Szyman Catherine M. CENTRAL INDEX KEY: 0001438538 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15525 FILM NUMBER: 24919118 MAIL ADDRESS: STREET 1: C/O EDWARDS LIFESCIENCES CORPORATION STREET 2: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER NAME: FORMER CONFORMED NAME: Szyman Catherine M DATE OF NAME CHANGE: 20080625 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edwards Lifesciences Corp CENTRAL INDEX KEY: 0001099800 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 364316614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9492502500 MAIL ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP. DATE OF NAME CHANGE: 20090225 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP DATE OF NAME CHANGE: 20000203 FORMER COMPANY: FORMER CONFORMED NAME: CVG CONTROLLED INC DATE OF NAME CHANGE: 19991126 4 1 doc4.xml X0508 4 2024-05-03 0001099800 Edwards Lifesciences Corp EW 0001438538 Szyman Catherine M. ONE EDWARDS WAY IRVINE CA 92614 1 CVP, Critical Care 0 Common Stock 2024-05-03 4 F 0 479.0000 85.0600 D 43222.4373 D Common Stock 2024-05-04 4 M 0 5796.0000 0 A 49018.4373 D Common Stock 2024-05-04 4 F 0 3442.0000 85.2500 D 45576.4373 D Performance Rights 2024-05-04 4 M 0 5796.0000 0.0000 D 2024-05-04 2028-05-03 Common Stock 5796.0000 0.0000 D On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan. Linda J. Park, Attorney-in-Fact 2024-05-06